海正生材晚间公告，中石化资本持有1078.82万股占5.32%，拟自公告披露后十五个交易日后的三个月内 通过集中竞价减持不超202.67万股，占公司总股本不超1%，减持期为2026年3月17日～2026年6月16 日，减持价格按届时市场价格确定，股份均为IPO前取得，减持原因为经营发展资金需求。 ...

证券代码：688203 证券简称：海正生材 公告编号：2026-04 浙江海正生物材料股份有限公司 首次公开发行部分限售股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 78,560,061股。 本次股票上市流通总数为78,560,061股。 本次股票上市流通日期为2026 年 2 月 24 日。因 2026 年 2 月 16 日至 23 日 为非交易日，上市流通日顺延至 2026 年 2 月 24 日。 （4）本公司承诺减持时遵守中国证券监督管理委员会、上海证券交易所有关 法律、法规或规范性文件的相关规定。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意浙江海正生物材料股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]847 号），同意公司首次公开发行股 票的注册申请。并经上海证券交易所同意，公司首次向社会公众公开发行 A 股股 票 50,669,517 股，并于 2022 年 8 月 16 日在 ...

中信建投证券股份有限公司 关于浙江海正生物材料股份有限公司 首次公开发行部分限售股票上市流通的核查意见 本次上市流通的限售股为公司首次公开发行部分限售股，共涉及限售股股东 1名，为公司控股股东浙江海正集团有限公司，持有公司限售股份数量为 78,560,061股，占公司当前总股本的38.76%。浙江海正集团有限公司所持股份原 限售期为公司股票上市之日起三十六个月，因触发承诺履行条件，其锁定期自动 延长6个月至2026年2月15日。现限售期即将届满，该部分限售股将于2026年2月 16日起上市流通，因2026年2月16日至23日为非交易日，上市流通日顺延至2026 年2月24日。 二、本次上市流通的限售股形成后至今公司股本数量变化情况 本次上市流通的限售股属于首次公开发行部分限售股。本次上市流通的限售 股形成至今，公司未发生因利润分配、公积金转增等导致股本数量变化的情况。 1 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"）作为 浙江海正生物材料股份有限公司（以下简称"海正生材"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股 ...

Group 1 - The company Hai Zheng Sheng Cai announced on February 2 that as of January 31, 2026, it has repurchased approximately 2.19 million shares through the Shanghai Stock Exchange, accounting for 1.078% of its total share capital of approximately 203 million shares [1] - The highest repurchase price was 15.98 yuan per share, while the lowest was 7.76 yuan per share, with a total expenditure of approximately 24.22 million yuan [1] Group 2 - The automotive sales giant Baolide, known for selling luxury cars such as Rolls-Royce and Porsche, is now undergoing bankruptcy liquidation, with its headquarters in Hangzhou reportedly vacant and its subsidiary in Yiwu sealed [1]

证券代码：688203 证券简称：海正生材 公告编号：2026-03 浙江海正生物材料股份有限公司 2025 年 8 月 18 日，公司召开第七届董事会第十七次会议审议通过了《关于调 整回购股份价格上限及延长实施期限的议案》，将回购股份价格上限由 12 元/股（含） 调整为 17 元/股（含），并同时对回购实施期限延长 6 个月，延长至 2026 年 2 月 27 日止，即回购实施期限为自 2024 年 8 月 28 日至 2026 年 2 月 27 日。具体内容 详见公司于 2025 年 8 月 19 日在上海证券交易所网站（www.sse.com.cn）披露的《浙 江海正生物材料股份有限公司关于调整回购股份价格上限及延长实施期限的公告》 （公告编号：2025-48）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，上市公司应当在每个月的前 3 个交易日内公告截 至上月末的回购进展情况。现将公司回购股份的进展情况公告如下： 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对 ...

Core Viewpoint - The company, Hai Zheng Sheng Cai (688203.SH), has announced a share buyback program, indicating a commitment to returning value to shareholders and potentially signaling confidence in its future performance [1] Group 1: Share Buyback Details - As of January 31, 2026, the company has repurchased a total of 2,185,500 shares, which represents 1.078% of its current total share capital [1] - The highest price paid for the repurchased shares was 15.98 CNY per share, while the lowest price was 7.76 CNY per share [1] - The total amount spent on the share buyback was 24,215,121.30 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company, Haizheng Shengcai (688203.SH), has announced a share buyback program, having repurchased a total of 2.1855 million shares as of January 31, 2026, which represents 1.078% of its total share capital of 203 million shares [1] - The highest price at which the shares were repurchased was 15.98 RMB per share, while the lowest price was 7.76 RMB per share [1] - The total amount spent on the share buyback was 24.2151 million RMB, excluding transaction fees such as stamp duty and trading commissions [1]

Core Viewpoint - Haizheng Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses for the company [1] - The transition of construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

Core Viewpoint - Haizheng Biomedical Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in higher depreciation and tax expenses, further squeezing profits for the period [1]

Core Viewpoint - Haizheng Shengcai (688203) expects a significant decline in net profit for the fiscal year 2025, projecting a profit of 7.5 million to 9.5 million yuan, representing a year-on-year decrease of 73.24% to 78.88% [2] Financial Performance - The company faces downward pressure on product sales prices, which has compressed the gross profit margin [2] - A decrease in interest income and foreign exchange gains has led to an increase in financial expenses for the period [2] - The transition of some construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further squeezing profits [2]